Single User License: $2750
Member Price: FREE
Use code SUMMER at checkout for 50% OFF
Already a member? Login to access this report free.
Report Highlights
The global market for renal biomarkers is estimated to increase from $1.2 billion in 2022 to reach $1.7 billion by 2027, at a compound annual growth rate (CAGR) of 7.6% from 2022 through 2027.
Report Includes
- 41 data tables and 24 additional tables
- A detailed overview and up-to-date analysis of the global markets for renal biomarkers
- Analyses of the global market trends, with market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation of the actual market size and revenue forecast for renal biomarkers market, and corresponding market share analysis by assay type, application, end user, and region
- Updated information on market drivers and opportunities for renal biomarkers, key shifts, regulations and industry specific challenges, and other demographic factors that will shape the market demand over the coming years (2022-2027)
- Identification of the companies best positioned to meet the demand owing to their proprietary technologies, product launches, mergers and acquisitions, and other market strategic advantages
- Review of recent industry structure for biomarkers, R&D activities, and analysis of the competitive landscape based on recent developments and segmental revenues
- Patent activity and review of patent grants for biomarkers and related technologies
- Descriptive company profiles of the market leading players, including BioMerieux, Gentian Diagnostic, Proteomics International, Thermo Fisher Scientific, SphingoTec, and BioPorto
Report Scope
This report incorporates an in-depth analysis of the renal biomarker market, including market estimations and trends through 2021. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the CAGR for renal biomarkers.
The scope of the report extends only to renal biomarker consumables and not devices used to study renal biomarkers. All types of renal biomarkers have been considered in research, clinical trials and for diagnostic purposes.
This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World (RoW) region. For market estimates, data is provided for 2021 as the base year, 2022 and forecast through year-end 2027.
Report Synopsis
Report Metrics | Details | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base year considered | 2021 | ||||||||||||||||
Forecast period considered | 2022-2027 | ||||||||||||||||
Base year market size | $1.1 billion | ||||||||||||||||
Market size forecast | $1.7 billion | ||||||||||||||||
Growth rate | CAGR of 7.6% for the forecast period of 2022-2027 | ||||||||||||||||
Units considered | $ Millions | ||||||||||||||||
Segments covered | Segment, Region, Country, Type, End-User, and Technique | ||||||||||||||||
Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||||||||
Countries covered | U.S., Canada, France, Germany, UK, Italy, Spain, China, Australia, and Japan | ||||||||||||||||
Key Market Drivers |
|
||||||||||||||||
Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The in vitro diagnostic renal biomarker market was valued at $771 million in 2013 and $812 million in 2014. The market is expected to reach $1.1 billion by 2019, a compound annual growth rate (CAGR) of 7% from 2014 to 2019.
Report Includes
- A comprehensive analysis of renal biomarkers global markets and technologies.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Details pertaining to the history and current state of chronic kidney disease (CKD), background information on renal biomarkers, and current industrial technologies used for diagnosis.
- In-depth analyses of the predominant biomarkers in the market, namely creatinine, and emerging biomarkers like NGAL, KIM-1, L-FABP and many others.
- Discussion concerning intellectual property, the regulatory requirement, and the competitive landscape of the industry.
- Comprehensive profiles of major players in the renal biomarkers field.
Related Reports
Companion Diagnostics: Technologies and Markets
The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.
Oncology Biomarkers: Global Markets
The global oncology biomarkers market reached $15.5 billion in 2022, should reach $17.6 billion by 2023 and $35.2 billion by 2028 with a compound annual growth rate (CAGR) of 14.9% during the forecast period of 2023-2028.
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.
Cardiac Biomarkers: Technologies and Global Markets
The global market for cardiac biomarkers is estimated to increase from $13.4 billion in 2022 to reach $23.8 billion by 2027, at a compound annual growth rate (CAGR) of 12.2% from 2022 through 2027.
Recent Reports
Global Single-cell Technologies Market
The global market for single-cell technologies is estimated to increase from $3.6 billion in 2023 to reach $9.2 billion by 2029, at a compound annual growth rate (CAGR) of 17.1% from 2024 through 2029.
Artificial Intelligence (AI) in Life Sciences Market
The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.
Global Automated and Closed Cell Therapy Market
The global market for automated and closed cell therapy is expected to grow from $1.8 billion in 2024 and is projected to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.9% during the forecast period of 2024 to 2029.
Theranostics: Global Markets
The global market for theranostics was valued at $3.7 billion in 2023. The market is expected to grow from $4.3 billion in 2024 to $12.7 billion by the end of 2029, at a compound annual growth rate, or CAGR, of 24.0% from 2024 to 2029.
Cell Therapy Biomanufacturing: Global Markets
The global market for cell therapy biomanufacturing is expected to grow from $9.7 billion in 2024 and is projected to reach $16.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2024 to 2029.
Top Trending Reports
Life Science Tools and Reagents: Global Markets
The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.
Wearable Medical Devices: Technologies and Global Markets
The global market for wearable medical devices was valued at $35.6 billion in 2023. This market is estimated to grow from $45.0 billion in 2024 to $151.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.5% from 2024 through 2029.
Carbon Credits Market: Global Outlook
This report provides an up-to-date analysis of current and future markets for carbon credits and the carbon offsets industry. It presents a thorough and up-to-date global assessment of the market and business of carbon credits. The report also includes a competitive landscape, ESG analysis, and detailed company profiles of leading market players.
Biodegradable Polymers: Global Markets and Technologies
The global market volumes of biodegradable polymers is expected to grow from 1,286.0 kilotons in 2023 and is projected to reach 4,140.0 kilotons by the end of 2028, at a compound annual growth rate (CAGR) of 26.3% during the forecast period of 2023 to 2028.
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets
The global market for radiation therapy products and radiopharmaceuticals is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More